GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NovelStem International Corp (OTCPK:NSTM) » Definitions » Sloan Ratio %

NovelStem International (NovelStem International) Sloan Ratio % : 0.00% (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is NovelStem International Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

NovelStem International's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.

Warning Sign:

When sloan ratio (-159.16)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, NovelStem International has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


NovelStem International Sloan Ratio % Historical Data

The historical data trend for NovelStem International's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovelStem International Sloan Ratio % Chart

NovelStem International Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.98 10.02 - - -159.16

NovelStem International Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NovelStem International's Sloan Ratio %

For the Diagnostics & Research subindustry, NovelStem International's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovelStem International's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where NovelStem International's Sloan Ratio % falls into.



NovelStem International Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

NovelStem International's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-4.187--0.348
--0.25)/2.255
=-159.16%

NovelStem International's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-4.221--0.393
--0.25)/2.401
=-149.02%

NovelStem International's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -2.875 (Jun. 2023 ) + -1.096 (Sep. 2023 ) + 0.053 (Dec. 2023 ) + -0.303 (Mar. 2024 ) = $-4.22 Mil.
NovelStem International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.169 (Jun. 2023 ) + -0.072 (Sep. 2023 ) + -0.079 (Dec. 2023 ) + -0.073 (Mar. 2024 ) = $-0.39 Mil.
NovelStem International's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + -0.25 (Mar. 2024 ) = $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovelStem International  (OTCPK:NSTM) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, NovelStem International has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


NovelStem International Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of NovelStem International's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


NovelStem International (NovelStem International) Business Description

Traded in Other Exchanges
N/A
Address
2255 Glades Road, Suite 221A, Boca Raton, FL, USA, 33431
NovelStem International Corp owns novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies. The technology is also being used for genetic research related to other medical therapies.
Executives
Baker Street Capital Management, Llc 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Vadim Perelman 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Baker Street Capital L.p. 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Stephen Gans director, 10 percent owner 14850 NW 44TH COURT, OPA LOCKA FL 33054
Shannon River Partners Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Fund Management Co Llc 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Partners Ii, Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Doonbeg Fund Lp 10 percent owner 850 THIRD AVE, 13TH FLOOR, New York ny 10022
Spencer M. Waxman director C/O SHANNON RIVER PARTNERS, 800 THIRD AVENUE 30TH FLOOR, NEW YORK NY 10022
Stanley Morgan 10 percent owner 1585 BROADWAY, NEW YORK NY 10036
Robert D. Epstein director 2255 GLADES ROAD, BOCA RATON FL 33431
Coghill Capital Management Llc 10 percent owner 233 SOUTH WACKER DRIVE, SUITE 8439, CHICAGO IL 60606
Ccm Master Fund Ltd 10 percent owner C/O MORGAN STANLEY FUND SERVICES (CAYMAN, LTD CENTURY YARD CRICKET SQ HUTCHINGS DR, PO BOX 2681 GEORGE TOWN E9 00000
Clint D Coghill 10 percent owner
Scott Gomez officer: Chief Accounting Officer

NovelStem International (NovelStem International) Headlines

From GuruFocus

NewStem Announces $4 million Seed Investment

By PRNewswire PRNewswire 07-16-2018